CLEAR CELL ADENOCARCINOMA OF THE VAGINA AND CERVIX SECONDARY TO INTRAUTERINE EXPOSURE TO DIETHYLSTILBESTROL

被引：59

作者：

HERBST, AL

ANDERSON, D

机构：

[1] Department of Obstetrics and Gynecology, University of Chicago, Chicago

来源：

SEMINARS IN SURGICAL ONCOLOGY | 1990年 / 6卷 / 06期

关键词：

chemotherapy; DES; epidemiology; hormone exposure; local therapy; surgery;

D O I：

10.1002/ssu.2980060609

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Intrauterine diethylstilbestrol (DES) exposure is associated with an increased risk for the development of clear cell adenocarcinoma (CCA) of the vagina and cervix. The age of the DES‐exposed patients has varied from 7 to 34 years with the highest frequency from 14 to 22 years. The risk among the exposed is small and is on the order of 1 per 1,000. Factors that may increase the risk are maternal history of prior miscarriage, exposure to DES in early gestation, a fall season of birth, and prematurity. Pregnancy does not appear to influence adversely the tumor characteristics or prognosis of patients who have developed these malignancies. Criteria for appropriate local therapy of small clear cell adenocarcinomas of the vagina are presented. Recurrent CCA has been observed as long as 20 years after primary therapy emphasizing the importance of prolonged follow‐up. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company

引用

页码：343 / 346

页数：4

共 17 条

[1]

Dodds EC, Goldberg L, Larson W, Robinson R, Oestrogenic activity of certain synthetic compounds, Nature, 141, pp. 247-248, (1938)

[2]

Dieckmann WJ, Davis MD, Rynkiewiez LM, Pottinger RE, Does administration of diethylstilbestrol during pregnancy have therapeutic value?, Am J Obstet Gynecol, 66, pp. 1062-1081, (1953)

[3]

FDA Drug Bulletin: Diethylstilbestrol Contraindicated in Pregnancy, (1971)

[4]

Herbst AL, Ulfelder H, Poskanzer DC, Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women, N Engl J Med, 284, pp. 878-881, (1971)

[5]

Herbst AL, Anderson D, Clear cell adenocarcinoma of cervix and vagina and DES‐related abnormalities, Gynecologic Oncology

[6]

Scully RE, Robboy SJ, Welch WR, Pathology and pathogenesis of diethylstilbestrol related disorders of the female genital tract, Intrauterine Exposure to Diethylstilbestrol in the Human, pp. 8-22, (1978)

[7]

Melnick S, Cole P, Anderson D, Herbst AL, Rates and risks of diethylstilbestrol‐related clear cell adenocarcinoma of the vagina and cervix, N Engl J Med, 316, pp. 514-516, (1987)

[8]

Herbst AL, Anderson S, Hubby MM, Haenszel WM, Kaufman RH, Risk factors for the development of diethylstilbestrol‐associated clear cell adenocarcinoma: A case‐control study, Am J Obstet Gynecol, 154, pp. 814-822, (1986)

[9]

Robboy SJ, Noller KL, O'Brien P, Et al., Increased incidence of cervical and vaginal dysplasia in 3,980 diethylstilbestrol‐exposed young women: Experience of the National Collaborative Diethylstilbestrol Adenosis Project, JAMA, 252, pp. 2979-2983, (1984)

[10]

Robboy SJ, Szyfelbein WM, Goellner JR, Et al., Dysplasia and cytologic findings in 4,589 young women enrolled in the Diethylstilbestrol‐Adenosis (DESAD) Project, Am J Obstet Gynecol, 140, pp. 579-586, (1981)

← 1 2 →